Antiprogestin method for reducing side effects associated with low dosage HRT and oral contraception
US7704983B1 · kind B1 · utility
53Cited by
10References
41Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 1, 1993 |
| Grant date | Apr 27, 2010 |
| Priority date | — |
| Expiry date | Sep 1, 2013 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/56
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Menses regulation and, when desired, contraception is achieved at low doses of estrogen and progestin, which otherwise would create episodes of breakthrough bleeding and/or withdrawal amenorrhea, by periodically inducing menses with an antiprogestin.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.